USDA confirmed highly pathogenic Avian influenza in commercial chickens in Mississippi
On Nov. 5, 2022, the U.S. Department of Agriculture’s (USDA) Animal Plant Health Inspection Service (APHIS) confirmed the…
On Nov. 5, 2022, the U.S. Department of Agriculture’s (USDA) Animal Plant Health Inspection Service (APHIS) confirmed the…
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
On Nov. 3, 2022, Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets…
On Nov. 1, 2022, Pfizer announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal…
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
On Oct. 27, 2022, Inovio Pharma announced that it has discontinued its internally funded efforts to develop INO-4800…
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
On Oct. 20, 2022, published results supported previous findings that the recombinant zoster vaccine Shingrix, recommended by the…
On Oct. 20, 2022, the National Institutes of Health announced that a three-dose course of the hepatitis B…
On Oct. 19, 2022, Pfizer and BioNTech announced that the European Medicines Agencyメs (EMA) Committee for Medicinal Products…
On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19…
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after…
On Oct. 18, 2022, global leaders confirmed US$ 2.6 billion in funding toward the Global Polio Eradication Initiative’s…
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, announced they had mutually agreed to cancel remaining…
On Oct. 13, 2022, researchers from the University of Oxford reported findings from a study exploring how certain…
On Oct. 13, 2022, Novavax announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination…
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
On Oct. 11, 2022, researchers from the University of Oxford have reported new findings from a Phase 1…
On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to…
On Oct. 10, 2022, Novavax announced that Switzerland’s Federal Office of Public Health had recommended Nuvaxovid (NVX-CoV2373) as…
On Oct. 7, 2022, the U.S. Food and Drug Administration approved Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and…
On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada had authorized COMIRNATY Original & Omicron BA.4/BA.5…
On Oct. 6, 2022, researchers in Japan released a study that described the development and application of the…
On Oct. 4, 2022, Washington University in St. Louis announced it had licensed the rights to develop, manufacture…
On Sept. 28, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
On Sept. 28, 2022, Moderna announced that the European Medicines Agency (EMA) had accepted a variation for the…
On Sept. 28, 2022, the Oregon Department of Agriculture and the U.S. Department of Agriculture’s Animal Plant Health…
On Sept. 27, 2022, the National Institutes of Health (NIH) announced that a large international study had confirmed…